NeuroSense Therapeutics (NRSN) Income towards Parent Company (2021 - 2024)

NeuroSense Therapeutics has reported Income towards Parent Company for 4 years, with the latest figure at $18.6 million in Q4 2024.

• Quarterly Income towards Parent Company rose 684.22% year-over-year to $18.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $3.9 million (down 61.32% YoY) and the FY2025 annual result came in at $11.1 million, up 8.96% from the prior year.
• Income towards Parent Company advanced to $18.6 million in Q4 2024 per NRSN's latest filing, from -$14.7 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $19.7 million in Q4 2022 and troughed at -$15.4 million in Q3 2022.
• A 4-year average of $1.6 million and a median of -$1.5 million in 2022 frame the typical range for Income towards Parent Company.
• The widest YoY moves for Income towards Parent Company: up 684.22% in 2024, down 4091.43% in 2024.
• Over 4 years, Income towards Parent Company stood at $7.2 million in 2021, then soared by 174.89% to $19.7 million in 2022, then tumbled by 116.19% to -$3.2 million in 2023, then surged by 684.22% to $18.6 million in 2024.
• According to Business Quant data, Income towards Parent Company over the past three periods registered $18.6 million, -$14.7 million, and $11.7 million for Q4 2024, Q3 2024, and Q2 2024 respectively.